NEW YORK (GenomeWeb News) – Venaxis, which is developing a multi-biomarker test for appendicitis, filed a shelf registration to publicly offer up to $20 million of its stock.

The Castle Rock, Colo.-based firm filed its Form S-3 with the US Securities and Exchange Commission after the close of the market on Tuesday to publicly offer its stock from time to time. A company spokesman said the firm currently has no specific offering planned.

Venaxis previously raised $14.4 million in May in a public offering of its shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.